Gene regulatory network inference from CRISPR perturbations in primary CD4+ T cells elucidates the genomic basis of immune disease.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
24 Oct 2023
24 Oct 2023
Historique:
pubmed:
25
9
2023
medline:
25
9
2023
entrez:
25
9
2023
Statut:
epublish
Résumé
The effects of genetic variation on complex traits act mainly through changes in gene regulation. Although many genetic variants have been linked to target genes in
Identifiants
pubmed: 37745614
doi: 10.1101/2023.09.17.557749
pmc: PMC10516010
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NHGRI NIH HHS
ID : R01 HG008140
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM139580
Pays : United States
Déclaration de conflit d'intérêts
Competing Interest Declaration A.M. is a co-founder of Arsenal Biosciences, Spotlight Therapeutics, and Survey Genomics, serves on the boards of directors at Spotlight Therapeutics and Survey Genomics, is a board observer (and former member of the board of directors) at Arsenal Biosciences, is a member of the scientific advisory boards of Arsenal Biosciences, Spotlight Therapeutics, Survey Genomics, NewLimit, Amgen, Tenaya, and Lightcast, owns stock in Arsenal Biosciences, Spotlight Therapeutics, NewLimit, Survey Genomics, PACT Pharma, Tenaya, and Lightcast and has received fees from Arsenal Biosciences, Spotlight Therapeutics, Survey Genomics, NewLimit, 23andMe, PACT Pharma, Juno Therapeutics, Tenaya, Lightcast, GLG, Gilead, Trizell, Vertex, Merck, Amgen, Genentech, AlphaSights, Rupert Case Management, Bernstein, and ALDA. A.M. is an investor in and informal advisor to Offline Ventures and a client of EPIQ. The Marson laboratory received research support from Juno Therapeutics, Epinomics, Sanofi, GlaxoSmithKline, Gilead and Anthem. Patent applications have been filed based on the findings described here. J.W.F. was a consultant for NewLimit, is an employee of Genentech, and has equity in Roche. A.B. is a stockholder in Alphabet, Inc. and a consultant for Third Rock Ventures. J.S.W was a consultant to Spiral Genetics.
Références
PLoS Genet. 2022 Jan 21;18(1):e1009666
pubmed: 35061661
Nature. 2023 Mar;615(7951):315-322
pubmed: 36755094
Immunol Rev. 2013 Mar;252(1):41-51
pubmed: 23405894
J Epidemiol. 2017 Mar;27(3S):S2-S8
pubmed: 28189464
Nucleic Acids Res. 2022 Jan 7;50(D1):D687-D692
pubmed: 34788843
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
Nature. 2023 Jan;613(7944):508-518
pubmed: 36653562
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Nat Genet. 2019 Jan;51(1):187-195
pubmed: 30478440
J Clin Immunol. 2022 Oct;42(7):1508-1520
pubmed: 36198931
Science. 2012 Sep 7;337(6099):1190-5
pubmed: 22955828
Nat Genet. 2019 Dec;51(12):1664-1669
pubmed: 31784727
Science. 2019 Jun 28;364(6447):1287-1290
pubmed: 31249060
Bioinformatics. 2012 Aug 15;28(16):2184-5
pubmed: 22743226
Nat Rev Mol Cell Biol. 2018 Apr;19(4):262-274
pubmed: 29209056
Nat Med. 2001 Aug;7(8):899-905
pubmed: 11479621
Nat Genet. 2015 Jun;47(6):569-76
pubmed: 25915600
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Genome Biol. 2019 May 16;20(1):94
pubmed: 31097038
Ann Rheum Dis. 2022 Jun 26;:
pubmed: 35753705
Elife. 2022 Dec 14;11:
pubmed: 36515579
Proc Natl Acad Sci U S A. 1995 May 23;92(11):4922-6
pubmed: 7761425
Nucleic Acids Res. 2023 Jan 6;51(D1):D587-D592
pubmed: 36300620
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Nat Genet. 2015 Mar;47(3):291-5
pubmed: 25642630
Science. 2020 Sep 11;369(6509):1318-1330
pubmed: 32913098
Nat Genet. 2018 Sep;50(9):1335-1341
pubmed: 30104761
Nature. 2017 Oct 11;550(7675):204-213
pubmed: 29022597
Cell. 2016 Nov 17;167(5):1369-1384.e19
pubmed: 27863249
Biostatistics. 2017 Apr 1;18(2):275-294
pubmed: 27756721
Oncogene. 2005 Apr 18;24(17):2899-908
pubmed: 15838523
Nature. 2022 Jun;606(7912):120-128
pubmed: 35545678
Genome Res. 2012 Sep;22(9):1790-7
pubmed: 22955989
Science. 2022 Apr 8;376(6589):eabf3041
pubmed: 35389779
Nucleic Acids Res. 2019 Jan 8;47(D1):D1056-D1065
pubmed: 30462303
Bioinformatics. 2016 Oct 1;32(19):3047-8
pubmed: 27312411
Cell. 2017 Jun 15;169(7):1177-1186
pubmed: 28622505
PLoS Genet. 2011 Feb;7(2):e1001317
pubmed: 21383966
Cell. 2019 May 2;177(4):1022-1034.e6
pubmed: 31051098
Nat Genet. 2015 Nov;47(11):1228-35
pubmed: 26414678
Nat Methods. 2012 Feb 28;9(3):215-6
pubmed: 22373907
Cell Genom. 2022 Jul 13;2(7):
pubmed: 35873673
Cytokine. 2012 Oct;60(1):38-42
pubmed: 22840496
Nat Genet. 2021 Sep;53(9):1300-1310
pubmed: 34475573
Nat Genet. 2022 Aug;54(8):1133-1144
pubmed: 35817986
Nat Rev Mol Cell Biol. 2022 Nov;23(11):732-749
pubmed: 35725906
Immunity. 2008 Dec 19;29(6):876-87
pubmed: 19062319
Front Genet. 2019 Sep 25;10:858
pubmed: 31608109
Mol Syst Biol. 2010 Jun 8;6:379
pubmed: 20531408
Nature. 2021 Feb;590(7845):290-299
pubmed: 33568819
Nat Rev Immunol. 2022 Dec;22(12):734-750
pubmed: 35508809
Annu Rev Immunol. 2010;28:445-89
pubmed: 20192806
Nat Genet. 2022 Nov;54(11):1640-1651
pubmed: 36333501